干扰素调节因子3及其可变剪接体与肿瘤

摘要/Abstract

摘要：干扰素调节因子3（IRF3）作为干扰素调节因子家族的重要成员，在调控Ⅰ型干扰素及其下游基因中发挥关键作用，并参与多种生物学过程。研究发现其可抑制肿瘤细胞的生长和转移，并诱导细胞凋亡，发挥抑癌基因作用。该作用机制涉及肿瘤免疫与炎症反应、凋亡及上皮间质转化等过程。IRF3可变剪接体可负性调控IRF3功能，影响肿瘤发生发展。相关的信号通路、发病机制研究为肿瘤早期诊断、治疗提供了新的思路。

关键词:干扰素调节因子3,剪接体,肿瘤

Abstract:As a member of interferon regulatory factor family (IRF), IRF3 plays an important role in triggering the expression of type Ⅰ interferons and downstream interferonstimulated genes, contributing to many biological process. Researches have found that it plays an antioncogene role in inhibiting tumor proliferation and migration, inducing cell apoptosis. The mechanism involves in tumor immunity and inflammatory reaction, apoptosis and epithelial mesenchymal transition. The alternative splicing isoforms of IRF3 act as negative modulators of IRF3 and affect tumor development progress. The recent signaling pathways and pathogenesis researches provide new ideas for early diagnosis and treatment of cancer.

Key words:Interferon regulatory factor3,Spliceosomes,Neoplasms

刘钟桧,孙丹,刘新民. 干扰素调节因子3及其可变剪接体与肿瘤[J]. 国际肿瘤学杂志, 2017, 44(3): 196-200.

Liu Zhonghui, Sun Dan, Liu Xinmin. Interferon regulatory factor3 and its alternative splicing isoforms in tumorLiu Zhonghui, Sun Dan, Liu Xinmin.[J]. Journal of International Oncology, 2017, 44(3): 196-200.

参考文献

［1］ Marsili G, Perrotti E, Remoli AL, et al. IFN regulatory factors and antiviral innate immunity: how viruses can get better［J］. J Interferon Cytokine Res, 2016, 36(7): 414-432. DOI: 10.1089/jir.2016.0002. ［2］ Yanai H, Negishi H, Taniguchi T. The IRF family of transcription factors: inception, impact and implications in oncogenesis［J］. Oncoimmunology, 2012, 1(8): 1376-1386. DOI: 10.4161/onci.22475. ［3］ Tarassishin L, Bauman A, Suh HS, et al. Antiviral and antiinflammatory mechanisms of the innate immune transcription factor interferon regulatory factor 3: relevance to human CNS diseases［J］. J Neuroimmune Pharmacol, 2013, 8(1): 132-144. DOI: 10.1007/s114810129360 5. ［4］ Ikushima H, Negishi H, Taniguchi T. The IRF family transcription factors at the interface of innate and adaptive immune responses［J］. Cold Spring Harb Symp Quant Biol, 2013, 78(78): 105-116. DOI: 10.1101/sqb.2013.78.020321. ［5］ Zhao GN, Jiang DS, Li H. Interferon regulatory factors: at the crossroads of immunity, metabolism, and disease［J］. Biochim Biophys Acta, 2015, 1852(2): 365-378. DOI: 10.1016/j.bbadis.2014.04.030. ［6］ Grandvaux N, Guan X, Yoboua F, et al. Sustained activation of interferon regulatory factor 3 during infection by paramyxoviruses requires MDA5［J］. J Innate Immun, 2014, 6(5): 650-662. DOI: 10.1159/000360764. ［7］ Andzinski L, Spanier J, Kasnitz N, et al. Growing tumors induce a local STING dependent Type Ⅰ IFN response in dendritic cells［J］. Int J Cancer, 2016, 139(6): 1350-1357. DOI: 10.1002/ijc.30159. ［8］ SterneWeiler T, Sanford JR. Exon identity crisis: diseasecausing mutations that disrupt the splicing code［J］. Genome Biol, 2014, 15(1): 201. DOI: 10.1186/gb4150. ［9］ Wang ET, Sandberg R, Luo S, et al. Alternative isoform regulation in human tissue transcriptomes［J］. Nature, 2008, 456(7221): 470-476. DOI: 10.1038/nature07509. ［10］ Wiszomirska H, PiekiekoWitkowska A, Nauman A. Disturbances of alternative splicing in cancer［J］. Postepy Biochem, 2011, 57(3): 257-265. ［11］ Abou Faycal C, Gazzeri S, Eymin B. RNA splicing, cell signaling, and response to therapies［J］. Curr Opin Oncol, 2016, 28(1): 58-64. DOI: 10.1097/CCO.0000000000000254. ［12］ BiselliChicote PM, Oliveira AR, Pavarino EC, et al. VEGF gene alternative splicing: pro and antiangiogenic isoforms in cancer［J］. J Cancer Res Clin Oncol, 2012, 138(3): 363-370. DOI: 10.1007/s0043201110732. ［13］ Anczuków O, Krainer AR. Splicingfactor alterations in cancers［J］ . RNA, 2016, 22(9): 1285-1301. DOI: 10.1261/rna.057919.116. ［14］ Li Y, Hu X, Song Y, et al. Identification of novel alternative splicing variants of interferon regulatory factor 3［J］. Biochim Biophys Acta, 2011, 1809(3): 166-175. DOI: 10.1016/j.bbagrm.2011.01.006. ［15］ Tiwari N, Gheldof A, Tatari M, et al. EMT as the ultimate survival mechanism of cancer cells［J］. Semin Cancer Biol, 2012, 22(3): 194-207. DOI: 10.1016/j.semcancer.2012.02.013. ［16］ Nieto MA, Huang RY, Jackson RA, et al. EMT: 2016［J］. Cell, 2016, 166(1): 21-45. DOI: 10.1016/j.cell.2016.06.028. ［17］ Gao D, Vahdat LT, Wong S, et al. Microenvironmental regulation of epithelialmesenchymal transitions in cancer［J］. Cancer Res, 2012, 72 (19): 4883-4889. DOI: 10.1158/00085472.CAN121223. ［18］ Xu P, BaileyBucktrout S, Xi Y, et al. Innate antiviral host defense attenuates TGFβ function through IRF3mediated suppression of Smad signaling［J］. Mol Cell, 2014, 56(6): 723-737. DOI: 10.1016/j.molcel.2014.11.027. ［19］ Zhu S, Li HB, Flavell RA. Resemble and inhibit: when RLR meets TGF beta［J］. Mol Cell, 2014, 56(6): 719-720. DOI: 10.1016/j.molcel.2014.12.010. ［20］ Pythoud C, Rothenberger S, MartínezSobrido L, et al. Lymphocytic choriomeningitis virus differentially affects the virusinduced type Ⅰ interferon response and mitochondrial apoptosis mediated by RIGⅠ/MAVS［J ］. J Virol, 2015, 89(12): 6240-6250. DOI: 10.1128/JVI.0061015. ［21］ Yuan MM, Xu YY, Chen L, et al. TLR3 expression correlates with apoptosis, proliferation and angiogenesis in hepatocellular carcinoma and predicts prognosis［J］. BMC Cancer, 2015, 15: 245. DOI: 10.1186/s1288501512625. ［22］ Gambara G, Desideri M, Stoppacciaro A, et al. TLR3 engagement induces IRF3dependent apoptosis in androgensensitive prostate cancer cells and inhibits tumour growth in vivo［J］. J Cell Mol Med, 2015, 19(2): 327-339. DOI: 10.1111/jcmm.12379. ［23］ Mantovani A. Molecular pathways linking inflammation and cancer［J］ . Curr Mol Med, 2010, 10(4): 369-373. ［24］ Mougiakakos D, Choudhury A, Lladser A, et al. Regulatory T cells in cancer［J］. Adv Cancer Res, 2010, 107: 57-117. DOI: 10.1016/S0065230X (10)07003X. ［25］ Guo R, Li Y, Ning J, et al. HnRNP A1/A2 and SF2/ASF regulate alternative splicing of interferon regulatory factor3 and affect immunomodulatory functions in human nonsmall cell lung cancer cells［J］. PLoS One, 2013, 8(4): e62729. DOI: 10.1371/journal.pone.0062729. ［26］ Szabo A, Fekete T, Koncz G, et al. RIGⅠ inhibits the MAPKdependent proliferation of BRAF mutant melanoma cells via MKP1［J］ . Cell Signal, 2016, 28(5): 335-347. DOI: 10.1016/j.cellsig.2016.01.012. ［27］ Duewell P, Beller E, Kirchleitner SV, et al. Targeted activation of melanoma differentiationassociated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma［J］. Oncoimmunology, 2015, 4(10): e1029698. DOI: 10.1080/2162402X.2015.1029698. ［28］ Liu B, Wang X, Chen TZ, et al. Polarization of M1 tumor associated macrophage promoted by the activation of TLR3 signal pathway［J］. Asian Pac J Trop Med, 2016, 9(5): 484-488. DOI: 10.1016/j.apjtm.2016.03.019. ［29］ Liu Y, Li T, Xu Y, et al. Effects of TLR4 gene silencing on the proliferation and apotosis of hepatocarcinoma HEPG2 cells［J］. Oncol Lett, 2016, 11(5): 3054-3060. ［30］ Muvaffak A, Pan Q, Yan H, et al. Evaluating TBK1 as a therapeutic target in cancers with activated IRF3［J］. Mol Cancer Res, 2014, 12(7): 1055-1066. DOI: 10.1158/15417786.MCR130642.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.